An issue of Endo International PLC (NASDAQ:ENDP) bonds rose 1.4% as a percentage of their face value during trading on Thursday. The high-yield debt issue has a 6% coupon and is set to mature on July 15, 2023. The bonds in the issue are now trading at $90.00 and were trading at $91.75 last week. Price changes in a company’s bonds in credit markets often predict parallel changes in its stock price.
Several analysts have commented on the stock. Mizuho reissued a “buy” rating and issued a $18.00 price target (up previously from $17.00) on shares of Endo International PLC in a research report on Thursday, April 13th. Zacks Investment Research raised shares of Endo International PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, May 2nd. JMP Securities reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Endo International PLC in a research note on Wednesday, March 15th. Leerink Swann reaffirmed a “market perform” rating on shares of Endo International PLC in a research note on Monday, March 20th. Finally, Canaccord Genuity set a $14.00 price target on shares of Endo International PLC and gave the stock a “hold” rating in a research note on Monday, May 1st. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $18.74.
Shares of Endo International PLC (NASDAQ:ENDP) opened at 10.77 on Friday. The stock’s market capitalization is $2.40 billion. Endo International PLC has a 52-week low of $9.70 and a 52-week high of $24.93. The stock has a 50 day moving average of $12.25 and a 200-day moving average of $12.75.
Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Tuesday, May 9th. The company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.13. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period last year, the business posted $1.08 EPS. The company’s revenue was up 7.7% on a year-over-year basis. Analysts predict that Endo International PLC will post $3.58 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of ENDP. Russell Investments Group Ltd. acquired a new stake in Endo International PLC during the fourth quarter worth $3,711,000. Gabelli Funds LLC increased its stake in Endo International PLC by 14.6% in the fourth quarter. Gabelli Funds LLC now owns 235,000 shares of the company’s stock worth $3,870,000 after buying an additional 30,000 shares during the period. Norges Bank acquired a new stake in Endo International PLC during the fourth quarter worth $26,929,000. State Street Corp increased its stake in Endo International PLC by 5.3% in the fourth quarter. State Street Corp now owns 9,642,033 shares of the company’s stock worth $158,792,000 after buying an additional 483,271 shares during the period. Finally, Macquarie Group Ltd. increased its stake in Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares during the period. Hedge funds and other institutional investors own 93.28% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Endo International PLC (ENDP) Bond Prices Rise 1.4%” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2017/06/17/endo-international-plc-endp-debt-trading-1-4-higher-updated.html.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.